Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Salivary Gland Neoplasms × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 49 Kidney Neoplasms 14 Neoplasms 12 Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 8 Melanoma 7 Colorectal Neoplasms 7 Carcinoma, Hepatocellular 7 Glioblastoma 5 Carcinoma 5 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Liver Neoplasms 2 Kidney Diseases 2 Advanced Solid Tumors 2 cT2a N0NxM0 Renal Tumor 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

Docetaxel 16 Cisplatin 14 Carboplatin 12 Magnetic Resonance Spectroscopy 9 Cetuximab 9 pembrolizumab 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Radiotherapy 7 Paclitaxel 7 Specimen Handling 6 Gemcitabine 6 Biopsy 6 Radiotherapy, Intensity-Modulated 5 Radiotherapy, Conformal 5 Chemotherapy, Adjuvant 5 Vorinostat 4 Taxes 4 Radiosurgery 4 Fluorodeoxyglucose F18 4 Capecitabine 4 Bevacizumab 4 darolutamide 3 Sorafenib 3 Radiation 3 Platinum 3 Nivolumab 3 Irinotecan 3 Immunohistochemistry 3 Goserelin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02857712 2019-08-30

SGC-AX14

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡